Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor

Journal of Dermatological Treatment

Volumn 17, Issue 3, 2006, Pages 160-161

  Santoro, Francesca ^a   Cozzani, Emanuele ^a   Parodi, Aurora ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE   (Italy)

Author keywords

EGF receptor; Side effect; Skin reaction

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; EMOLLIENT AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; HYDROXYZINE;

ACNE; AGED; ARTICLE; CASE REPORT; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; ECZEMA; EDEMA; ERYTHEMA; HAIR DISEASE; HUMAN; HYPERPIGMENTATION; LUNG NON SMALL CELL CANCER; MALE; NAIL DISEASE; PRIORITY JOURNAL; PRURITUS; SKIN DEFECT; SKIN DISEASE; SKIN EXFOLIATION; SKIN FISSURE; SKIN MANIFESTATION; SOLID TUMOR; TELANGIECTASIA; XEROSIS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSIS, DIFFERENTIAL; DRUG ERUPTIONS; HUMANS; LUNG NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33746616943     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600688523     Document Type: Article

References (7)

1. Segaert S, van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16:1425-33.
2. Gutzmer R, Werfel T, Kapp A, Elsner J. Cutaneous side effects of EGF-receptor inhibition and their management. Hautarzt. 2006;57:509-13.
3. Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, et al. The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges. 2005;3:599-606.
4. Nanney LB, Magid M, Stoscheck CM, King LE Jr. Comparison of epidermal growth factor binding and receptor distribution in normal human epidermis and epidermal appendages. J Invest Dermatol. 1984;83:385-93.
5. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/ EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005;23:5235-46.
6. Perez-Soler R, Delord JP, Halpern A, Kelly K, Krueger J, Sureda BM, et al. HER1/EGFR inhibitor-associated rash: future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum. Oncologist. 2005;10:345-56.
7. Perez-Soler R. Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome? Oncology. 2003;17(11 suppl 12), 23-8.